Drugs / BNC101
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02726334 | Mar 2016 → Dec 2017 | colorectal cancer | Bionomics Limited | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BNC101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02726334 ↗ |
| Modality | Monoclonal antibody | “BNC101 (Anti-LGR5 Humanized Monoclonal Antibody)” NCT02726334 ↗ |
| Route | Intravenous | “Administered via IV infusion once a week over 60 minutes (1 hour).” NCT02726334 ↗ |
| Target | LGR5 | “BNC101 (Anti-LGR5 Humanized Monoclonal Antibody)” NCT02726334 ↗ |